Intercept fibrosis endpoint ‘most meaningful’ to regulators: B. Riley FBR

Intercept fibrosis endpoint ‘most meaningful’ to regulators, says B. Riley FBR. B. Riley FBR analyst Mamtani said after Intercept reported results from the Phase 3 REGENERATE trial in non-alcoholic steatohepatitis that he was most encouraged by the doubling of drug effect on the fibrosis endpoint with a high statistical significance and “relatively clean” safety profile. The analyst, who reiterated his view that the fibrosis endpoint is the most clinically meaningful endpoint in the eyes of the regulators and payers globally, keeps a Buy rating and $155 price target on Intercept shares.

https://thefly.com/landingPageNews.php?id=2866263